Objective: Selected estrogen receptor b-selective phytoestrogen (phytoSERM), a preparation of genistein, daidzein, and S-equol, has an 83-fold selective affinity for estrogen receptor (ER) b, and may promote neuronal survival and estrogenic mechanisms in the brain without exerting feminizing activity in the periphery. The aim of this study was to assess the safety, tolerability, and single-dose pharmacokinetics of the phytoSERM formulation in perimenopausal and postmenopausal women.
T he search for a safe approach to promote estrogenic signaling in the brain, without eliciting adverse effects, [1] [2] [3] has focused on the development of tissue-selective estrogen receptor (ER) modulators (SERMs). In recent years, selective estrogen receptor-b (ERb) targeting has been attempted in the development of therapies for a range of conditions including cognitive impairment and menopausal symptoms. There are plausible mechanisms by which ERb stimulation could lead to improved cognition, feelings of well-being, reduced risk for cognitive impairment, and improved vasomotor symptoms. [4] [5] [6] [7] [8] [9] We sought to develop a rationally designed formulation composed of selected ERb-selective phytoestrogens (phytoSERMs) that could provide greater cognitive or vasomotor effect than various nutraceuticals that are blended with both ERa and ERb modulators. The phytoSERM formulation exhibits an 83-fold selectivity for ERb over ERa, and induces synergistic rather than antagonistic effects on various neuronal outcomes. 10 The formulation enhances ERb-mediated responses by combining S-equol, genistein, and daidzein in equal parts. Equol in the phytoSERM formulation serves the purpose of moderating the potential influences of interindividual differences in the metabolism of daidzein by intestinal bacteria.
Various studies have reported on the pharmacokinetics of the individual components of the phytoSERM formulation or a combination of daidzein and genistein only. [11] [12] [13] [14] Similar to steroidal estrogens, isoflavones undergo enterohepatic circulation and appear in the bile soon after oral administration. The typical biphasic appearance of isoflavone metabolites in plasma after ingestion suggests that they are initially absorbed in the duodenum and proximal jejunum, and then the colon. [15] [16] [17] We expected the pharmacokinetics of daidzein and genistein in this combination to be similar to each of these isoflavones alone. We expected also a prolonged apparent elimination half-life with S-equol, because about 25% to 30% of participants likely will convert daidzein to equol by intestinal bacteria 18 that should start to appear in plasma 6 to 8 hours after daidzein intake.
We report here on the single-dose pharmacokinetics, acute tolerability, and adverse events of the phytoSERM formulation in perimenopausal and postmenopausal women. Such knowledge is important in determining the characteristics and optimal doses of this phytoSERM formulation, and serves as a stepping stone for the design of future clinical trials aimed at assessing its safety and effectiveness for cognitive and functional improvement.
METHODS

Study product and doses
Study products included 50 and 100 mg of phytoSERM or placebo-containing film-coated tablets composed of equal amounts of genistein, dadzein, and S-equol, or placebo. Thus the 50-mg tablet contained 16.7 mg of each of genistein, daidzein, and S-equol; and the 100-mg tablet contained 33.3 mg of each constituent.
The phytoSERM combination and identically appearing and tasting placebo tablets were manufactured to current Good Manufacturing Practices standards and supplied by MeriCal, Inc (Vista, CA). Each active supplement raw material and excipient were catalogued, tested for identification using Fourier-transform infrared spectroscopy instrumentation, and verified for potency by Certificate of Analysis. All ingredients were weighed and blended according to a detailed formulation sheet, and compressed into tablet form (oval 8.5 mm Â 15.5 mm).
Dosage selection was based on preclinical experiments, 10, 19, 20 past studies of isoflavones individually and combined, and the dosage used in various soy extract products that are marketed as food supplements regarding safety and chronic exposure that are generally between 50 and 100 mg of isoflavones.
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Study design
The first 18 participants of 71 randomized into a doseranging, double-blinded, placebo-controlled 12-week clinical trial evaluating cognitive performance and vasomotor symptoms (Clinicaltrials.gov NCT 01723917) were included in this single-dose, 24-hour pharmacokinetics study. Six women were included in each of the three treatment groups (Table 1) . Eligible participants were generally healthy perimenopausal to postmenopausal women, aged 45 to 60 years, with intact uteri and ovaries, whose last natural menstrual cycle completed from at least 2 months to less than 4 years before screening. Participants had at least one cognitive complaint and one vasomotor-related symptom based on the Memory Function Questionnaire and Greene Climacteric Scale. 22, 23 For this pharmacokinetic study, participants were asked to abstain from food containing soy for at least 2 days before the baseline visit and their taking the first tablet. Participants swallowed one tablet in the morning, in the presence of the study staff. Blood samples were obtained before and 2, 4, 6, 8, and 24 hours after administration of the first dose. Blood was obtained by venipuncture and collected into 6-mL lithiumheparin Vacutainer tubes. Plasma was collected after centrifugation at 1,000g for 20 minutes at 48C. Aliquots were catalogued and then stored at À808C in a designated laboratory at the USC School of Pharmacy before being shipped for analysis. All study participants were monitored and observed for any adverse events or complaints during the first 8 hours and at 24 hours after the single tablet. Safety assessments included vital signs and direct observation of any new signs or symptoms emerging during this time interval. Participants then continued in the randomized trial, taking a tablet of study medication per day for 12 weeks.
Plasma phytoestrogen assays and pharmacokinetic analysis
Plasma concentrations of genistein, dihydrogenistein (DHGE), daidzein, dihydrodaidzein (DHDE), O-demethylangolensin (DMA), and equol were analyzed by a previously established method using isotope dilution high-performance liquid chromatography (HPLC) electrospray ionization (negative mode) tandem mass spectrometry at the University of Hawaii Cancer Center. 24 Limits of quantitation (LOQ) for all analytes were 5 nM for genistein, DHGE, daidzein, DHDE, and DMA, and 20 nM for equol. All 108 samples (18 participants with six samples each) were processed in one batch to limit variability. Between-day coefficients of variation ranged between 4% and 18% for all analytes, whereas intraday variation was no more than half of that.
Statistical analysis
Characteristics of the study sample were summarized and compared between the three dose groups using analysis of variance (ANOVA) for continuous variables and Fisher's exact HERNANDEZ ET AL test for categorical variables. Using the participant-level timeconcentration data for each analyte, pharmacokinetic parameters were calculated for each participant: C max (peak plasma concentration), t max (time at peak plasma concentration), AUC (area under the time-concentration curve), and t 1/2 (terminal elimination half-life). AUC was calculated over 0 to 24 hours using the trapezoidal rule to estimate the AUC between sampling times in the terminal part of the curve. The t 1/2 parameter was estimated as ln (2) divided by the elimination rate; the elimination rate was calculated as the linear regression slope of log concentration versus sampling time fit over the last three sampling times (6, 8 , and 24 hours). The pharmacokinetic (PK) parameters were summarized and compared between the 50 mg phyto-b-SERM, 100 mg phyto-b-SERM, and placebo groups using nonparametric Kruskal-Wallis tests; P values for post hoc pair-wise comparisons were adjusted for multiplicity using a Hochberg correction. All analyses used the pharmacokinetic and other statistical modules of STATA Version 13 software (StataCorp. 2013, Stata Statistical Software: Release 13, StataCorp LP, College Station, TX).
RESULTS
Demographics of study participants
Eighteen women were enrolled in the pharmacokinetic study, and compliance was 100%. The three groups had similar characteristics ( Table 1 ). The overall mean age was 53 years, and the overall mean BMI was 26.15. The majority was of non-Hispanic ethnicity (78%) and the number of years since their last menstrual period ranged from means 1.5 to 3.2 per group. Demographics of the individual dose groups are described in Table 1 .
Plasma genistein, daidzein, and equol pharmacokinetics
A summary of the pharmacokinetic data is presented in Table 2 . The plasma concentrations for the three parent isoflavones after a single oral administration of the phytoSERM tablet in both the 50 and 100-mg cohorts are shown in Figs. 1A and 2B, respectively, and as log-linear plots in Figs. 1B and 2B. The 50-mg dose of the phytoSERM preparation yielded (mean AE SD) a C max of 570 AE 143 nM, a T max of 9 AE 3 hours, and an elimination phase half-life of 7.5 AE 1.1 hours for genistein; a C max of 622 AE 128 nM, a T max of 6 AE 1 hours, and an elimination phase half-life of 8.1 AE 1.2 hours for daidzein; and a C max of 781.2 AE 123 nM, a T max of 4.3 AE 1 hours, and an elimination phase half-life of 8.9 AE 2.1 hours for equol.
There was a dose-dependent difference in the plasma concentrations for the three parent compounds. The AUCs for genistein, daidzein, and equol were significantly greater in the 100-mg dose (all P < 0.025), indicating a dose-proportional change in concentration with the phytoSERM treatment. The time to reach maximum concentration (T max ) varied among the three constituents, from 4 to 9 hours, and was not dose-dependent. Elimination half-life for all three phytoestrogens did not significantly differ between the 50 and 100-mg doses. The log-linear plots of plasma concentration time curves during the 24-hour sampling period for the three parent compounds of both the 50 and 100-mg doses exhibited a linear slope for the terminal portion of the curve, demonstrating that elimination follows first-order kinetics (Figs. 1B and 2B). We provided the plasma appearance and disappearance curves for specific phytoestrogens for each participant in each cohort (placebo, 50 mg dose and 100 mg dose) in the supplemental digital content. These data show both the interindividual heterogeneity of the pharmacokinetics of the phytoSERM formulation, and the clear dose-related plasma level differences in the parent compounds (see Supplemental Digital Content 1, http://links.lww.com/MENO/A257).
Safety
No treatment-emergent adverse events or complaints were observed or elicited after the single-dose oral administration of the phytoSERM combination during the 24-hour study period. No signs and symptoms of any adverse events were reported by the 18 participants during the 24-hour period.
DISCUSSION
Widely marketed dietary phytoestrogen supplements contain genistein and daidzein alone or in combination, but do not contain S-equol, which makes this phytoSERM formulation unique. Genistein and daidzein occur natively in soy products, but S-equol is exclusively produced through the metabolism of daidzein by intestinal microbiota after the intake of daidzein or daidzein-containing products including soy. 11 Wide variations exist across populations in the ability to produce equol from daidzein; about 25% to 35% of Western adults have an equolproducing phenotype compared with 50% to 65% of Asian 
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populations. [25] [26] [27] Adding equol to this phytoSERM preparation is a strategy to minimize such individual variations and to ensure an effect in both phenotypes. The development of the phytoSERM combination is based on a foundation of preclinical science indicating that the equimolar combination of genistein, daidzein, and S-equol can function as an efficacious phytoestrogen combination to selectively target ERb. 10, 20 The phytoSERM combination showed a clear dose-proportional increase in concentration exposures in healthy perimenopausal and postmenopausal women with cognitive complaints. After oral administration, genistein, daidzein, and equol rapidly appeared in plasma and reached maximum concentrations between 4 and 6 hours after ingestion. In contrast to previous studies that reported concentrations of genistein being consistently higher than those of daidzein, 12, 15, 28 plasma concentrations of genistein were about the same as those of daidzein in our study. Equol, however, showed higher concentrations at each time point than either genistein or daidzein. This was probably due to a two-fold exposure to S-equol, primarily by its presence in the oral formulation, and secondarily by its formation through the gut bacteria from dihydrodaidzein in a minority of participants.
Plasma concentration appearance and disappearance curves of genistein, daidzein, and S-equol are similar to those of previous studies. 11, 12, 15, 24, 29 The elimination half-life of approximately 8 hours for all three components in the 50-mg cohort is also consistent with other reports. 11, 12 The elimination half-life for genistein and daidzein in the 100-mg cohort, however, was about twice as long-14.5 and 13.1 hours, respectively (the t 1/2 for equol may be confounded by daidzein metabolism in the gut). The near tripling of the AUC with the 100 mg genistein high dose and the decrease in the dihydrogenistein and dihydrodaidzein metabolites suggest that CYP 1A2, required for metabolism of genistein and daidzein is saturated at this dose.
As described previously, 30 the plasma equol concentration appearance and disappearance curve suggested that it had a much higher bioavailability and a slower elimination than genistein and daidzein. Equol was absorbed more rapidly at both doses than genistein and daidzein, showing a t max of about 4.5 hours, compared with about 9 and 6 hours for genistein and daidzein, respectively. At 2 hours, the plasma concentration of S-equol was about twice that of genistein and daidzein. Such rapid appearance of S-equol in plasma is consistent with previous reports. 11, 31 Pharmacokinetic parameters for S-equol were similar to the ones reported in previous studies, 11, 21, 32, 33 wherein dosages were used that ranged from 10 to 30 mg and showed t max ranges of 1 to 6 hours, a t 1/2 range of 4.9 to 8.2 hours, and C max ranging widely from 991 AE 129 to 4,953 AE 747 nM/L. Differences in t max and C max values between the phytoSERM combination and other studies may be accounted for by differences among the formulations and whether they were administered with or without meals.
CONCLUSIONS
The phytoSERM combination was well-tolerated, appeared without adverse effects, and exhibited a favorable pharmacokinetic profile. After single oral administration of 50 and 100-mg tablets of the formulation the phytoestrogens genistein, daidzein and S-equol were rapidly absorbed, reached detectable plasma concentrations, and showed a dose-proportional increase in concentration exposures in their pharmacokinetics. The formulation may prove to be advantageous for several perimenopausal and postmenopausal conditions.
